The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 10, 2014, Pages 1835-1841

  Sanz Sanz, Arturo ^a   Niranjan, Yashavanthi ^b   Hammarén, Henrik ^b   Ungureanu, Daniela ^b   Ruijtenbeek, Rob ^c   Touw, Ivo P ^a   Silvennoinen, Olli ^b,d   Hilhorst, Riet ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c PamGene International BV   (Netherlands)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

JAK2 recombinant protein; Kinetic mechanism; Multiplex kinetic assay; Peptide microarray

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 2; JH2 ENZYME; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; ENZYME ACTIVITY; ENZYME KINETICS; MUTATION; PRIORITY JOURNAL; WILD TYPE;

EID: 84928102345     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.07.003     Document Type: Article

References (29)

1. P. Saharinen, K. Takaluoma, and O. Silvennoinen Regulation of the JAK2 tyrosine kinase by its pseudokinase domain Mol. Cell. Biol. 20 10 2000 3387 3395 (Pubitemid 30243884)
2. P. Saharinen, M. Vihinen, and O. Silvennoinen Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain Mol. Biol. Cell 14 4 2003 1448 1459 (Pubitemid 36547413)
3. D. Ungureanu, J. Wu, T. Pekkala, Y. Niranjan, C. Young, and O.N. Jensen et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling Nat. Struct. Mol. Biol. 18 9 2011 971 976
4. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, and S. Swanton et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 9464 2005 1054 1061 (Pubitemid 40386783)
5. C. James, V. Ugo, J. Le Couédic, J. Staerk, F. Delhommeau, and C. Lacout et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 7037 2005 1144 1148 (Pubitemid 40663494)
6. R. Kralovics, F. Passamonti, A.S. Buser, S. Teo, R. Tiedt, and J.R. Passweg et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders N. Engl. J. Med. 352 17 2005 1779 1790 (Pubitemid 40570926)
7. R.L. Levine, M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, and B.J. Huntly et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 4 2005 387 397 (Pubitemid 40544655)
8. J.L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, and R. Marchioli et al. Chronic myeloproliferative disorders ASH Education Program Book 2003(1) 2003 200 224
9. A. Sanz, D. Ungureanu, T. Pekkala, R. Ruijtenbeek, I.P. Touw, and R. Hilhorst et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation PLoS ONE 6 4 2011 e18522
10. R. Hilhorst, L. Houkes, A. van den Berg, and R. Ruijtenbeek Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A Anal. Biochem. 387 2 2009 150 161
11. I. Segel Steady-state kinetics of multireactant enzymes Enzyme Kinet. 1975 505 515
12. J.W. Trauger, F. Lin, M.S. Turner, J. Stephens, and P.V. LoGrasso Kinetic mechanism for human rho-kinase II (ROCK-II) Biochemistry (N. Y.) 41 28 2002 8948 8953 (Pubitemid 34774408)
13. S. Whitehouse, J. Feramisco, J. Casnellie, E. Krebs, and D. Walsh Studies on the kinetic mechanism of the catalytic subunit of the cAMP-dependent protein kinase J. Biol. Chem. 258 6 1983 3693 3701
14. P.V. LoGrasso, B. Frantz, A.M. Rolando, S.J. O'Keefe, J.D. Hermes, and E.A. O'Neill Kinetic mechanism for p38 MAP kinase Biochemistry (N. Y.) 36 34 1997 10422 10427 (Pubitemid 27374134)
15. M.M. Keshwani, and T.K. Harris Kinetic mechanism of fully activated S6K1 protein kinase J. Biol. Chem. 283 18 2008 11972 11980
16. P. Chène Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases Drug Discov. Today 13 11 2008 522 529
17. C.V. Parast, B. Mroczkowski, C. Pinko, S. Misialek, G. Khambatta, and K. Appelt Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis Biochemistry (N. Y.) 37 47 1998 16788 16801 (Pubitemid 28543942)
18. D. Erdmann, B. Allard, J. Bohn, A. De Pover, A. Floersheimer, and P. Fontana et al. Kinetic study of human full-length wild-type JAK2 and V617F mutant proteins Open Enzyme Inhib. J. 1 2008 80 84
19. T. Hall, T.L. Emmons, J.E. Chrencik, J.A. Gormley, R.A. Weinberg, and J.W. Leone et al. Expression, purification, characterization and crystallization of non-and phosphorylated states of JAK2 and JAK3 kinase domain Protein Expr. Purif. 69 1 2010 54 63
20. M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, and A. Sheehy et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 16 6 2009 487 497
21. L. Zhao, Y. Ma, J. Seemann, and L. Huang A regulating role of the JAK2 FERM domain in hyperactivation of JAK2 (V617F) Biochem. J. 426 2010 91 98
22. L. Zhao, H. Dong, C.C. Zhang, L. Kinch, M. Osawa, and M. Iacovino et al. A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation J. Biol. Chem. 284 39 2009 26988 26998
23. L.M. Scott, W. Tong, R.L. Levine, M.A. Scott, P.A. Beer, and M.R. Stratton et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N. Engl. J. Med. 356 5 2007 459 468 (Pubitemid 46193073)
24. R.M. Bandaranayake, D. Ungureanu, Y. Shan, D.E. Shaw, O. Silvennoinen, and S.R. Hubbard Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F Nat. Struct. Mol. Biol. 19 2012 754 759
25. I.S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, and S.E. Broughton et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor Blood 107 1 2006 176 183 (Pubitemid 43053540)
26. Y. Shan, K. Gnanasambandan, D. Ungureanu, E.T. Kim, H. Hammarén, and K. Yamashita et al. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase Nat. Struct. Mol. Biol. 21 2014 579 584
27. P.J. Lupardus, M. Ultsch, H. Wallweber, P. Bir Kohli, A.R. Johnson, and C. Eigenbrot Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition Proc. Natl. Acad. Sci. U. S. A. 111 22 2014 Jun 3 8025 8030
28. O. Hantschel Structure, regulation, signaling, and targeting of Abl kinases in cancer Genes Cancer 3 5-6 2012 436 446
29. V. Yu, J. Pistillo, I. Archibeque, J. Han Lee, B. Sun, and L.B. Schenkel et al. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings Exp. Hematol. 41 2013 491 500